[{"id":"fe52e481-e906-4f7f-a53f-550a7128a15c","acronym":"EVANGELINE","url":"https://clinicaltrials.gov/study/NCT05607004","created_at":"2022-11-07T13:56:21.386Z","updated_at":"2025-02-25T12:38:26.751Z","phase":"Phase 2","brief_title":"(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer","source_id_and_acronym":"NCT05607004 - EVANGELINE","lead_sponsor":"Atossa Therapeutics, Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 214","initiation":"Initiation: 02/14/2023","start_date":" 02/14/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2025-02-24"},{"id":"dc4d04a6-0615-4ba1-8e7e-f73bd8437cb0","acronym":"CAAA603B12101","url":"https://clinicaltrials.gov/study/NCT05870579","created_at":"2023-05-23T16:06:09.074Z","updated_at":"2025-02-25T14:42:04.037Z","phase":"Phase 1","brief_title":"[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer","source_id_and_acronym":"NCT05870579 - CAAA603B12101","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • fulvestrant • goserelin acetate • AAA603"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 11/13/2023","start_date":" 11/13/2023","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 01/26/2032","study_completion_date":" 01/26/2032","last_update_posted":"2025-02-14"},{"id":"a8e4ef32-1344-482b-a5f5-187c3f5e9c87","acronym":"YATAGARASU","url":"https://clinicaltrials.gov/study/NCT04325828","created_at":"2021-01-18T20:57:18.226Z","updated_at":"2025-02-25T15:26:19.647Z","phase":"Phase 2","brief_title":"A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma","source_id_and_acronym":"NCT04325828 - YATAGARASU","lead_sponsor":"Janssen Pharmaceutical K.K.","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 04/07/2020","start_date":" 04/07/2020","primary_txt":" Primary completion: 06/09/2021","primary_completion_date":" 06/09/2021","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-10"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"2e071664-2674-4d6f-b1a9-33056e7adbe4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02115282","created_at":"2021-01-17T17:34:12.805Z","updated_at":"2025-02-25T16:43:48.211Z","phase":"Phase 3","brief_title":"Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic","source_id_and_acronym":"NCT02115282","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • Jingzhuda (entinostat) • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 608","initiation":"Initiation: 03/29/2014","start_date":" 03/29/2014","primary_txt":" Primary completion: 05/05/2020","primary_completion_date":" 05/05/2020","study_txt":" Completion: 06/25/2025","study_completion_date":" 06/25/2025","last_update_posted":"2025-02-06"},{"id":"9663b458-bf8e-4744-aded-694ba1c51e6a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06348134","created_at":"2024-04-04T16:39:16.597Z","updated_at":"2025-02-25T13:56:14.439Z","phase":"Phase 2","brief_title":"Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery","source_id_and_acronym":"NCT06348134","lead_sponsor":"University of Chicago","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • letrozole • goserelin acetate • Soltamox (tamoxifen citrate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 07/01/2034","primary_completion_date":" 07/01/2034","study_txt":" Completion: 07/01/2036","study_completion_date":" 07/01/2036","last_update_posted":"2025-02-05"},{"id":"0ed50171-eed5-449a-810c-57f1bdbbcb80","acronym":"OFSET","url":"https://clinicaltrials.gov/study/NCT05879926","created_at":"2023-05-30T14:05:14.431Z","updated_at":"2025-02-25T16:55:01.814Z","phase":"Phase 3","brief_title":"Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25","source_id_and_acronym":"NCT05879926 - OFSET","lead_sponsor":"NRG Oncology","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e triptorelin • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 3960","initiation":"Initiation: 08/31/2023","start_date":" 08/31/2023","primary_txt":" Primary completion: 01/01/2032","primary_completion_date":" 01/01/2032","study_txt":" Completion: 07/01/2034","study_completion_date":" 07/01/2034","last_update_posted":"2025-02-04"},{"id":"85a83785-b733-4534-88fe-4b08d1977f8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04126070","created_at":"2021-01-18T20:09:27.547Z","updated_at":"2025-02-25T14:28:48.143Z","phase":"Phase 2","brief_title":"Nivolumab + Docetaxel + ADT in MHSPC Patients with DDRD or Inflamed Tumors","source_id_and_acronym":"NCT04126070","lead_sponsor":"Xiao X. Wei, MD","biomarkers":" PD-L1 • BRCA1 • MSI • CD8 • MLH1 • MSH6 • MSH2 • CDK12 • CHEK2 • BRIP1 • RAD51C • RAD51D • NBN • ABRAXAS1 • GEN1","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR","tags":["PD-L1 • BRCA1 • MSI • CD8 • MLH1 • MSH6 • MSH2 • CDK12 • CHEK2 • BRIP1 • RAD51C • RAD51D • NBN • ABRAXAS1 • GEN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • docetaxel • goserelin acetate • Firmagon (degarelix) • leuprolide acetate for depot suspension"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/11/2020","start_date":" 05/11/2020","primary_txt":" Primary completion: 10/24/2024","primary_completion_date":" 10/24/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-01-29"},{"id":"5ab5758f-ded0-479b-83dd-b16b495d0f1a","acronym":"FASCINATE-N","url":"https://clinicaltrials.gov/study/NCT05582499","created_at":"2022-10-17T13:56:00.115Z","updated_at":"2025-02-25T12:29:07.250Z","phase":"Phase 2","brief_title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","source_id_and_acronym":"NCT05582499 - FASCINATE-N","lead_sponsor":"Fudan University","biomarkers":" HER-2 • PGR • CD8 • FOXC1","pipe":"","alterations":" ","tags":["HER-2 • PGR • CD8 • FOXC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • AiRuiLi (adebrelimab) • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Recruiting","enrollment":" Enrollment 716","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-12-27"},{"id":"d08e3cfd-4eeb-458a-9218-3225ed8135e4","acronym":"NePtune","url":"https://clinicaltrials.gov/study/NCT05498272","created_at":"2022-09-18T06:19:44.875Z","updated_at":"2025-02-25T15:00:34.026Z","phase":"Phase 2","brief_title":"Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations","source_id_and_acronym":"NCT05498272 - NePtune","lead_sponsor":"Rana McKay, MD","biomarkers":" BRCA1 • BRCA2","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • triptorelin • goserelin acetate • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-10-24"},{"id":"204a3645-717f-42ed-9810-3a60efcecc4a","acronym":"BTCRC-HN17-111","url":"https://clinicaltrials.gov/study/NCT03942653","created_at":"2021-01-18T19:24:28.517Z","updated_at":"2025-02-25T16:09:07.413Z","phase":"Phase 2","brief_title":"Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma","source_id_and_acronym":"NCT03942653 - BTCRC-HN17-111","lead_sponsor":"Manish Patel","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/30/2019","start_date":" 05/30/2019","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-10-11"},{"id":"cf8bf0b5-ca6f-4f6e-a44f-54ab88c53b60","acronym":"FACILE","url":"https://clinicaltrials.gov/study/NCT03944434","created_at":"2021-01-18T19:25:17.328Z","updated_at":"2025-02-25T15:43:30.551Z","phase":"Phase 2","brief_title":"FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT03944434 - FACILE","lead_sponsor":"Fondazione Sandro Pitigliani","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • letrozole • anastrozole • triptorelin • goserelin acetate • leuprolide acetate for depot suspension"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 12/27/2018","start_date":" 12/27/2018","primary_txt":" Primary completion: 12/27/2024","primary_completion_date":" 12/27/2024","study_txt":" Completion: 11/27/2025","study_completion_date":" 11/27/2025","last_update_posted":"2024-09-25"},{"id":"63ba93fd-a0f6-4865-ad2d-03267b454c0a","acronym":"S1802","url":"https://clinicaltrials.gov/study/NCT03678025","created_at":"2021-07-05T17:17:10.086Z","updated_at":"2025-02-25T16:31:34.107Z","phase":"Phase 3","brief_title":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","source_id_and_acronym":"NCT03678025 - S1802","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" SYP","pipe":"","alterations":" ","tags":["SYP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • abiraterone acetate • prednisone • Eligard (leuprolide acetate) • bicalutamide • triptorelin • goserelin acetate • flutamide • nilutamide • Firmagon (degarelix) • Viadur (leuprorelin implant)"],"overall_status":"Recruiting","enrollment":" Enrollment 1273","initiation":"Initiation: 09/24/2018","start_date":" 09/24/2018","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 10/01/2031","study_completion_date":" 10/01/2031","last_update_posted":"2024-08-16"},{"id":"65b36a7f-90c2-4880-b9b4-47e4dcace750","acronym":"NEOLETRIB","url":"https://clinicaltrials.gov/study/NCT05163106","created_at":"2021-12-20T15:53:29.600Z","updated_at":"2025-02-25T15:54:15.951Z","phase":"Phase 2","brief_title":"Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole","source_id_and_acronym":"NCT05163106 - NEOLETRIB","lead_sponsor":"University Hospital, Akershus","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • letrozole • goserelin acetate"],"overall_status":"Completed","enrollment":" Enrollment 85","initiation":"Initiation: 12/01/2022","start_date":" 12/01/2022","primary_txt":" Primary completion: 07/30/2024","primary_completion_date":" 07/30/2024","study_txt":" Completion: 07/30/2024","study_completion_date":" 07/30/2024","last_update_posted":"2024-08-02"},{"id":"4004e195-6fa4-408f-8f56-450ccd6489c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06528210","created_at":"2025-02-25T16:02:53.341Z","updated_at":"2025-02-25T16:02:53.341Z","phase":"Phase 2","brief_title":"Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer","source_id_and_acronym":"NCT06528210","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • bicalutamide • triptorelin • goserelin acetate • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-07-30"},{"id":"893db886-c712-4cce-b597-bb3b00601a44","acronym":"DISCOVARY","url":"https://clinicaltrials.gov/study/NCT05694819","created_at":"2023-01-23T14:59:43.274Z","updated_at":"2025-02-25T17:25:58.308Z","phase":"Phase 2","brief_title":"Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)","source_id_and_acronym":"NCT05694819 - DISCOVARY","lead_sponsor":"National Cancer Center Hospital East","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nubeqa (darolutamide) • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 04/17/2020","start_date":" 04/17/2020","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-06-21"},{"id":"2a11f2ce-d7a1-4499-9adf-7f2d5fda7036","acronym":"ROSALINE","url":"https://clinicaltrials.gov/study/NCT04551495","created_at":"2021-01-18T21:45:49.585Z","updated_at":"2024-07-02T16:34:26.568Z","phase":"Phase 2","brief_title":"Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)","source_id_and_acronym":"NCT04551495 - ROSALINE","lead_sponsor":"Jules Bordet Institute","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rozlytrek (entrectinib) • letrozole • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-06-13"},{"id":"75f0b64e-2f38-4d3f-986a-4f0367fd8684","acronym":"BOUQUET","url":"https://clinicaltrials.gov/study/NCT04931342","created_at":"2022-05-03T17:53:37.321Z","updated_at":"2024-07-02T16:34:26.433Z","phase":"Phase 2","brief_title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","source_id_and_acronym":"NCT04931342 - BOUQUET","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ER","pipe":"","alterations":" ","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • paclitaxel • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • cyclophosphamide • letrozole • ipatasertib (RG7440) • triptorelin • goserelin acetate • Itovebi (inavolisib) • giredestrant (RG6171)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 176","initiation":"Initiation: 10/07/2021","start_date":" 10/07/2021","primary_txt":" Primary completion: 05/30/2028","primary_completion_date":" 05/30/2028","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-06-13"},{"id":"9fe0152c-72e1-4a52-bb9d-c984450578a4","acronym":"ARCH","url":"https://clinicaltrials.gov/study/NCT05700903","created_at":"2023-01-26T15:02:58.180Z","updated_at":"2024-07-02T16:34:26.941Z","phase":"Phase 4","brief_title":"Contributions to Hypertension With Androgen Deprivation Therapy","source_id_and_acronym":"NCT05700903 - ARCH","lead_sponsor":"University of Colorado, Denver","biomarkers":" LCN2","pipe":"","alterations":" ","tags":["LCN2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • bicalutamide • goserelin acetate • flutamide • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 228","initiation":"Initiation: 09/20/2023","start_date":" 09/20/2023","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2024-06-12"},{"id":"7b8dfa1c-2da2-4d1b-8945-ea6ec1ea6662","acronym":"","url":"https://clinicaltrials.gov/study/NCT05720260","created_at":"2023-02-09T15:00:11.511Z","updated_at":"2024-07-02T16:34:27.630Z","phase":"Phase 2","brief_title":"Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC","source_id_and_acronym":"NCT05720260","lead_sponsor":"National Taiwan University Hospital","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • fulvestrant • Truqap (capivasertib) • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 01/17/2023","start_date":" 01/17/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-06-10"},{"id":"469f79f5-7bed-470f-bde8-dd6a3a9d7203","acronym":"GO39932","url":"https://clinicaltrials.gov/study/NCT03332797","created_at":"2021-01-17T18:03:30.772Z","updated_at":"2024-07-02T16:34:37.744Z","phase":"Phase 1","brief_title":"A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer","source_id_and_acronym":"NCT03332797 - GO39932","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • triptorelin • goserelin acetate • giredestrant (RG6171)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 181","initiation":"Initiation: 11/27/2017","start_date":" 11/27/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-06"},{"id":"0ed5b400-4576-472b-ab4d-5b13bfb5010f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03860987","created_at":"2021-01-18T19:02:51.031Z","updated_at":"2024-07-02T16:34:37.919Z","phase":"Phase 2","brief_title":"Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer","source_id_and_acronym":"NCT03860987","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • abiraterone acetate • prednisone • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 04/30/2019","start_date":" 04/30/2019","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2024-06-05"},{"id":"43fbfbcb-f326-4024-95a0-b6bf5afd97c2","acronym":"DETECT V","url":"https://clinicaltrials.gov/study/NCT02344472","created_at":"2021-01-18T11:08:55.334Z","updated_at":"2025-02-25T13:34:30.541Z","phase":"Phase 3","brief_title":"Detect V / CHEVENDO (Chemo vs. Endo)","source_id_and_acronym":"NCT02344472 - DETECT V","lead_sponsor":"Prof. Wolfgang Janni","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • capecitabine • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • letrozole • vinorelbine tartrate • anastrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 271","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-06-04"},{"id":"130d64cc-8174-4099-9fdc-c77e00468d6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02003209","created_at":"2021-01-18T09:08:50.149Z","updated_at":"2024-07-02T16:35:02.395Z","phase":"Phase 3","brief_title":"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer","source_id_and_acronym":"NCT02003209","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" TILs","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • goserelin acetate • Herwenda (trastuzumab biosimilar) • Paletan (pertuzumab biosimilar) • EG1206A (pertuzumab biosimilar) • GB221 (coprelotamab) • HS627 (pertuzumab biosimilar) • Pertuvia (pertuzumab biosimilar) • SIBP-01 (trastuzumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 315","initiation":"Initiation: 01/15/2014","start_date":" 01/15/2014","primary_txt":" Primary completion: 10/31/2016","primary_completion_date":" 10/31/2016","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-21"}]